The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Future Oncol
; 17(20): 2563-2571, 2021 Jul.
Article
em En
| MEDLINE
| ID: mdl-33769069
Lay abstract One of the key challenges in treating acute myeloid leukemia is to prevent relapse after remission has been achieved. This means that developing an effective maintenance treatment is very important. Maintenance treatment is given for a prolonged period and so it needs to be easy to give and well tolerated. Oral azacitidine is an example of this type of treatment and is the first drug that has been shown to improve survival as maintenance therapy for acute myeloid leukemia patients. This article describes the key studies that led to the approval of this important therapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Leucemia
Base de dados:
MEDLINE
Assunto principal:
Uridina
/
Síndromes Mielodisplásicas
/
Leucemia Mieloide Aguda
/
Aprovação de Drogas
/
Decitabina
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Austrália